Genfit (GNFT) News Today → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free GNFT Stock Alerts $3.80 +0.11 (+2.98%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 11:09 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Genfit (NASDAQ:GNFT)HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Genfit in a report on Wednesday.May 15 at 5:48 AM | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Quarter 2024 Financial InformationMay 14 at 4:10 PM | globenewswire.comGENFIT Reports First Quarter 2024 Financial InformationApril 27, 2024 | marketbeat.comGenfit (NASDAQ:GNFT) Stock Price Up 1.2%Genfit (NASDAQ:GNFT) Stock Price Up 1.2%April 25, 2024 | globenewswire.comGENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)April 15, 2024 | globenewswire.comGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsApril 5, 2024 | globenewswire.comGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FApril 5, 2024 | marketbeat.comGenfit's (GNFT) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Genfit in a research note on Friday.April 5, 2024 | finanznachrichten.deGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateApril 4, 2024 | globenewswire.comGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateApril 3, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday TradingApril 2, 2024 | marketbeat.comGenfit S.A. (NASDAQ:GNFT) Short Interest UpdateGenfit S.A. (NASDAQ:GNFT - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 98,900 shares, an increase of 15.1% from the February 29th total of 85,900 shares. Based on an average daily trading volume, of 18,700 shares, the short-interest ratio is currently 5.3 days. Approximately 0.2% of the company's stock are sold short.March 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday TradingMarch 5, 2024 | marketbeat.comGenfit S.A. (NASDAQ:GNFT) Sees Large Increase in Short InterestGenfit S.A. (NASDAQ:GNFT - Get Free Report) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 93,400 shares, an increase of 8.4% from the January 31st total of 86,200 shares. Based on an average daily volume of 28,100 shares, the days-to-cover ratio is currently 3.3 days. Currently, 0.2% of the company's shares are sold short.February 29, 2024 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2023February 25, 2024 | thestreet.comGENFIT S.A.February 16, 2024 | msn.comInventiva drops after adverse event in Phase 3 trial for NASH drugFebruary 8, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Genfit S.A.'s FY2026 Earnings (NASDAQ:GNFT)Genfit S.A. (NASDAQ:GNFT - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 EPS estimates for Genfit in a report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.67) per share for the year. The consensus estimate forFebruary 7, 2024 | marketbeat.comLeerink Partnrs Research Analysts Boost Earnings Estimates for Genfit S.A. (NASDAQ:GNFT)Genfit S.A. (NASDAQ:GNFT - Free Report) - Equities research analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Genfit in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings oFebruary 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday TradingJanuary 29, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Monday TradingJanuary 4, 2024 | marketbeat.comGenfit S.A. (NASDAQ:GNFT) Short Interest Down 8.5% in DecemberGenfit S.A. (NASDAQ:GNFT - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 100,000 shares, a drop of 8.5% from the November 30th total of 109,300 shares. Based on an average daily volume of 17,800 shares, the short-interest ratio is currently 5.6 days. Approximately 0.2% of the shares of the company are sold short.December 21, 2023 | benzinga.comGenfit Stock (NASDAQ:GNFT) Dividends: History, Yield and DatesDecember 20, 2023 | morningstar.comGenfit SA ADR GNFTDecember 7, 2023 | msn.comFDA grants priority review of Genfit-Ipsen liver disease drugDecember 7, 2023 | markets.businessinsider.comIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCNovember 17, 2023 | benzinga.comGENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023November 9, 2023 | finance.yahoo.comGENFIT Reports Third Quarter 2023 Financial InformationNovember 9, 2023 | msn.comOil Stocks Buoy European Equities Traded in the US as American Depositary Receipts ThursdayNovember 7, 2023 | msn.comOil Stocks Burden European Equities Traded in the US as American Depositary Receipts TuesdaySeptember 26, 2023 | finance.yahoo.comGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic TechnologySeptember 26, 2023 | finance.yahoo.comGENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 22, 2023 | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate UpdateSeptember 20, 2023 | finance.yahoo.comGENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate UpdateSeptember 15, 2023 | fool.comGenfit (NASDAQ: GNFT)August 28, 2023 | marketbeat.comFY2024 Earnings Forecast for Genfit S.A. (NASDAQ:GNFT) Issued By Leerink PartnrsGenfit S.A. (NASDAQ:GNFT - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2024 EPS estimates for Genfit in a note issued to investors on Thursday, August 24th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of $0.28 for the year,August 16, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Higher WednesdayAugust 14, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week on Down NoteJune 30, 2023 | msn.comGenfit’s Liver Disease Candidate Delivers Promising Phase 3 ResultsJune 16, 2023 | markets.businessinsider.comKepler Capital Keeps Their Buy Rating on Genfit (GNFTF)June 8, 2023 | msn.comPORTZAMPARC BNP PARIBAS Maintains Genfit (EPA:GNFT) Buy RecommendationJune 7, 2023 | finance.yahoo.comGENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023June 4, 2023 | marketbeat.comO Shaughnessy Asset Management LLC Trims Stock Holdings in Genfit S.A. (NASDAQ:GNFT)O Shaughnessy Asset Management LLC cut its holdings in shares of Genfit S.A. (NASDAQ:GNFT - Get Rating) by 63.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,882 shares of the company's stock after selliJune 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Genfit SA (GNFT)May 31, 2023 | finance.yahoo.comSeal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)May 31, 2023 | finance.yahoo.comGENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage AssetMay 23, 2023 | finance.yahoo.comGENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of HepatologyApril 19, 2023 | finance.yahoo.comGENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory DocumentsJanuary 5, 2023 | finance.yahoo.comGENFIT to Participate in Upcoming Investor ConferencesOctober 30, 2022 | marketbeat.comGenfit S.A. (NASDAQ:GNFT) Sees Significant Drop in Short InterestGenfit S.A. (NASDAQ:GNFT - Get Rating) saw a significant drop in short interest in October. As of October 15th, there was short interest totalling 157,200 shares, a drop of 10.6% from the September 30th total of 175,800 shares. Based on an average daily trading volume, of 41,900 shares, the short-interest ratio is presently 3.8 days. Approximately 0.3% of the shares of the stock are short sold. Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… GNFT Media Mentions By Week GNFT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNFT News Sentiment▼0.580.55▲Average Medical News Sentiment GNFT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNFT Articles This Week▼60▲GNFT Articles Average Week Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adverum Biotechnologies News Compugen News Elevation Oncology News Cellectis News Fennec Pharmaceuticals News Kodiak Sciences News X4 Pharmaceuticals News Century Therapeutics News INmune Bio News Cardiff Oncology News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNFT) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
